. 2023 May 30;93(3):1181–1193. doi: 10.3233/JAD-230167

Table 3.

Wilcox-Test results for pairwise comparisons between CTE stages, unadjusted for multiple comparison and adjusted for multiple comparisons (Benjamini & Hochberg)

Vitreous	No CTE	Versus CTE		Versus CTE		CTE Stage I/II	Versus CTE		CTE Stage III/IV
Biomarker		Stage I/II		Stage III/IV		(low stage)	Stage III/IV		(high stage)
	Median (IQR)	p	p ^#	p	p ^#	Median (IQR)	p	p ^#	Median (IQR)
tTau, pg/mL	743000	0.20	0.29	0.78	0.78	5340000	0.18	0.30	710000
	(167000– 2080000)					(661000– 7770000)			(112000– 3030000)
	n = 15					n = 5			n = 19
pTau₁₈₁, U/mL	260 (102– 424)	>0.99	>0.99	0.70	>0.99	196 (154– 207)	0.72	>0.99	290 (126– 466)
	n = 15					n = 5			n = 19
pTau₂₃₁, U/mL	7390 (1090– 24600)	0.40	0.58	0.58	0.58	15500 (5190– 20100)	0.29	0.58	3620 (410– 22200)
	n = 15					n = 5			n = 18
Aβ₄₀, pg/mL	482 (361– 612)	0.27	0.40	0.22	0.40	458 (98.4– 466)	0.95	0.95	417 (250– 535)
	n = 15					n = 5			n = 19
Aβ₄₂, pg/mL	30 (19– 34.8)	0.07^*	0.20	0.26	0.26	10.1 (2.07– 15.6)	0.21	0.26	21.9 (10.7– 32.3)
	n = 15					n = 5			n = 19
NfL, pg/mL	1020 (665– 2660)	0.06^*	0.096^*	0.27	0.27	6700 (4040– 16600)	0.01^**	0.03^**	848 (282– 2160)
	n = 12					n = 5			n = 15
Eotaxin-1, pg/mL	56.1 (25.9– 115)	>0.99	>0.99	0.17	0.50	51.7 (36– 120)	0.49	0.74	31.4 (14.8– 71.4)
	n = 15					n = 5			n = 18

p = unadjusted p value and p^# = p value after adjusting for multiple comparisons testing. ^*p < 0.10 and ^**p < 0.05. IQR, interquartile range; AD, Alzheimer’s disease; CTE, chronic traumatic encephalopathy; Aβ, amyloid-β; tTau, total tau; pTau, phosphorylated tau; NfL, neurofilament light; pg/mL, picograms per milliliter; U/mL, units per milliliter.